In vivo treatment with fexaramine, an intestine-restricted FXR agonist, results in less weight gain, lower insulin resistance, decreased hepatic steatosis and increased beiging of adipose tissue in diet-induced obese (DIO) mice38, these beneficial effects being dependent on gut microbiota and BA/TGR5 signaling39,40. The gene discussed is NR1H4; the disease is Insulin resistance.